Screener
Organon OGN D&A
D&A at other companies
Other financials
Where this comes from
Reported directly by Organon in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Organon’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 8:46 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-029532
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash Flows from Operating Activities | ||
| Net income | $146 | $87 |
| Adjustments to reconcile net income to net cash flows provided by operating activities: | ||
| Depreciation | 39 | 34 |
| Amortization | 47 | 50 |
| Acquired in-process research and development and milestones | — | 6 |
| Accretion and changes in fair value in contingent consideration | (5) | 11 |
| Deferred income tax expense (benefit) | 3 | (17) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Organon's D&A?
- Organon (OGN) reported D&A of $39M in Q1 2026.
- How has Organon's D&A changed year-over-year?
- Organon's D&A increased by 14.7% year-over-year, from $34M to $39M.
- What is the long-term trend for Organon's D&A?
- Over 4 years (2021 to 2025), Organon's D&A has grown at a 14.1% compound annual growth rate (CAGR), from $92M to $156M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Organon's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude